Multivirus-specific cytotoxic T lymphocytes - ViraCyte

Drug Profile

Multivirus-specific cytotoxic T lymphocytes - ViraCyte

Alternative Names: Multivirus-specific cytotoxic T lymphocyte therapy; Prelym

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Herpesvirus infections; Polyomavirus infections

Most Recent Events

  • 01 Sep 2017 ViraCyte completes a phase I/II trial in Adenovirus infections, Cytomegalovirus infections, Epstein-Barr virus infections, Herpesvirus infections, Polyomavirus infections in USA (IV) (NCT01570283)
  • 18 Jul 2017 Efficacy data from a phase I/II trial in Adenovirus infection, BK virus, Cytomegalovirus, Epstein-barr virus and Human herpesvirus released by Viracyte
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top